129 Electroactive drug delivery for local glioblastoma treatment
Clicks: 3
ID: 326833
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #214 of 219 articles by views in journal of neuro-oncology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 219 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction Despite recent advances in cancer therapeutics, the prognosis for glioblastoma remains exceptionally poor, stemming from the limited ability of systemically administered chemotherapeutics to cross the blood brain barrier (BBB). Mechanically circumventing the BBB represents a promising avenue. However, biomaterials previously used for local delivery suffer from low control over drug release, further limiting their translation. To address this, an implantable bioelectronic drug delivery device was developed to enable targeted, ‘on demand’ voltage-controlled solid-phase drug release. The device is designed to be compatible with neurosurgical workflows Method Drug release from the device is triggered by externally applying +2V (DC) to the device for 0.5 h. Voltage-triggered release of doxorubicin has been quantified using fluorospectrometric techniques. The cytotoxic (CellTiterGlo) and metabolic effects (liquid chromatography mass spectrometry) of voltage-triggered drug release from the device have been investigated in a 2D and 3D patient derived glioblastoma models. Devices were also implanted in vivo in an orthotopic mouse model (SB28) during the terminal surgery, with the brains cryosectioned to assess spread of doxorubicin. Results Voltage-mediated cytotoxicity of doxorubicin has been demonstrated in 2D and 3D patient derived glioblastoma models, with safety of the material and electrical stimulation alone confirmed in vitro. Further, release into mouse brain tumours confirmed greater doxorubicin diffusion under active release, a finding also confirmed in a similar study but in agarose gel brain tissue phantoms. Conclusions This device shows promise for targeted, ‘dry’ delivery of a chemotherapeutic drug within a short time window (0.5h). Plans are underway to commence a pilot in vivo study to investigate the safety and efficacy of this device in an SB28 orthotopic mouse brain tumour model.
| Reference Key |
openalex_W7204491943
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Joshua Killilea, Immi Van Der Auweraert, Gary Shaw, Harveena Padda, H.D. Briggs, Une Kontrimaite, Leire Landeira Suquia, Rosalie De Ferm, Lucia Moreno Gimeno, Phoebe McCrorie, Estelle Cuttaz, A Lee, Giovanni Carlo Miceli, Dr Stuart Smith, Dong-Hyun Kim, Ruman Rahman, Juanita Lopez, Roberto Portillo‐Lara, Josef Goding, Heiko Wurdak, Ryan Mathew, Christopher Chapman, Rylie Green |
| Journal | journal of neuro-oncology |
| Year | 2026 |
| DOI |
10.1093/neuonc/noag172.039
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.